Lonza Group has been granted a patent for a predictive model that forecasts parameter concentrations in cell cultures. The model uses multivariate techniques to predict future concentrations based on initial data and historical information. This innovation allows for proactive adjustments to maintain quality attributes within desired ranges. GlobalData’s report on Lonza Group gives a 360-degree view of the company including its patenting strategy. Buy the report here.
According to GlobalData’s company profile on Lonza Group, Nanoemulsion cosmetics was a key innovation area identified from patents. Lonza Group's grant share as of May 2024 was 59%. Grant share is based on the ratio of number of grants to total number of patents.
Predictive model for maintaining cell culture quality attributes
A recently granted patent (Publication Number: US11999939B2) discloses a process for propagating a cell culture that involves determining the concentration of quality attributes, measuring attribute influencing parameters, and utilizing a predictive model to calculate future attribute concentrations. The process includes running simulations on an optimizer to manipulate parameters within the cell culture and selectively changing conditions to maintain quality attribute concentrations within preset limits. The quality attributes can include lactate, protein, glycan, charge variants, aggregates, disulfide oxidation, or shuffling variants. The process also involves changing the nutrient media fed to the cell culture, adjusting flow rates, and potentially altering pH levels to achieve desired outcomes.
Furthermore, the patent outlines the use of a predictive model that employs multivariate methods to forecast future attribute concentrations, particularly focusing on maintaining lactate concentration within specified limits. The process aims to increase the titer concentration of the cell culture, which may contain mammalian cells, through a batch process lasting from 12 hours to 28 days before harvesting. By integrating predictive modeling, parameter manipulation, and selective condition changes, this patented process offers a systematic approach to optimizing cell culture propagation and quality attribute control, potentially enhancing efficiency and productivity in biopharmaceutical manufacturing processes.
To know more about GlobalData’s detailed insights on Lonza Group, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.